Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
This grant funds preclinical proof of concept studies aimed at developing treatments for rare diseases.
About this program
The Preclinical Proof of Concept Studies for Rare Diseases grant supports innovative research projects that focus on the early stages of treatment development for rare diseases. This funding opportunity is designed for researchers and institutions that are working on novel therapeutic approaches that have the potential to significantly impact patient care in rare disease populations. The goal is to advance promising ideas from the laboratory to a stage where they can be further developed into clinical trials. Eligible applicants include academic institutions, nonprofit organizations, and small businesses that are engaged in biomedical research. The grant encourages collaboration among researchers, clinicians, and industry partners to foster the development of new therapies. Projects should demonstrate a clear path toward clinical application and address unmet medical needs in rare diseases, ensuring that the research has the potential to lead to significant advancements in treatment options.
Eligibility
Academic institutions, nonprofit organizations, and small businesses engaged in biomedical research.